BioNTech SE (BNTX) Reports Q1 EPS of EUR14.24, Reiterates FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
BioNTech Announces First Quarter Financial Results and Corporate Update
May 9, 2022 6:01 AM EDTFirst quarter revenues of 6.4Â billion1, net income of 3.7Â billion and fully diluted earnings per share of 14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of 13 billion to 17 billionFirst-in-class CAR-T program targeting CLDN-6 (BNT211) in solid tumors showed manageable safety profile and signs of clinical activity; preliminary Phase 1/2 data presented at AACR Annual Meeting 2022Continued pipeline expansion to 16 clinical stage oncology programs in 20 ongoing clinical trialsÂ
Conference call and webcast scheduled for May 9, 2022, at 8:00 am ET (2:00 pm CET)
... More